novarock-admin

NovaRock Biotherapeutics Announces Exclusive License Agreement with CSPC to Develop and Commercialize NBL-012 in Select International Territories

October 21st, 2022

Ewing, NJ, October 20, 2022– NovaRock Biotherapeutics Ltd., a clinical-stage biotechnology company focusing on the development of innovative antibody therapies […]

News Comments Off on NovaRock Biotherapeutics Announces Exclusive License Agreement with CSPC to Develop and Commercialize NBL-012 in Select International Territories

NovaRock Biotherapeutics to Present at the 10th Annual Immuno-Oncology Summit 2022

October 13th, 2022

Ewing, NJ, October 13, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]

News Comments Off on NovaRock Biotherapeutics to Present at the 10th Annual Immuno-Oncology Summit 2022

NovaRock Biotherapeutics Presents a Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 10th, 2022

Ewing, NJ, April 10, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]

News Comments Off on NovaRock Biotherapeutics Presents a Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022

NovaRock Biotherapeutics Announces Exclusive LICENSE AGREEMENT and STRATEGIC PARTNERSHIP with Flame BioSciences

August 24th, 2021

NovaRock granted Flame Biosciences exclusive license (excluding China, Hong Kong, Macau, and Taiwan) to co-develop, manufacture, and commercialize NBL-015, a […]

News Comments Off on NovaRock Biotherapeutics Announces Exclusive LICENSE AGREEMENT and STRATEGIC PARTNERSHIP with Flame BioSciences

NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-015

May 25th, 2021

Ewing, NJ, May 24, 2021– NovaRock Biotherapeutics Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared […]

News Comments Off on NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-015

NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Gastric Cancer

April 7th, 2021

Ewing, NJ, April 7, 2021 – NovaRock Biotherapeutics Ltd announced today that their investigational new drug, NBL-015, a Claudin18.2 eADCC […]

News Comments Off on NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Gastric Cancer

NovaRock Biotherapeutics Announces Two E-Posters to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021

March 30th, 2021

Ewing, NJ, March 30, 2021 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]

News Comments Off on NovaRock Biotherapeutics Announces Two E-Posters to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021

NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases

January 6th, 2021

Ewing, NJ, January 6, 2021 – NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) has […]

News Comments Off on NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases

NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer

December 3rd, 2020

Ewing, NJ, December 3, 2020 – NovaRock Biotherapeutics Ltd, announced today that their investigational new drug, NBL-015, has been granted […]

News Comments Off on NovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer